MORRIS PLAINS, N.J., Oct. 1, 2015 /PRNewswire/ --  Xybion Corporation announced today that Novo Nordisk (NYSE: NVO) has selected Xybion's Pristima® Suite to manage all its non-GLP pharmacology studies in a global setting. The Pristima Suite is a preclinical software platform that offers a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and animal studies throughout the preclinical research process. 

Pristima Preclinical Software Platform

Xybion will provide a number of services and improvements to the Pristima platform to support non-GLP pharmacology studies, enabling Novo Nordisk to leverage the system for early drug discovery studies. In addition, Xybion will provide critical training and implementation services to configure Pristima and prepare the user community to meet Novo Nordisk best practices and reporting specifications.

Dr. Pradip Banerjee, CEO at Xybion stated, "Xybion is delighted to welcome Novo Nordisk to our client community; this opens yet another chapter in the Pristima history and is a further testament to the configurability that our engineers have built into the product. Our strategies facilitate scientists' research activities, improve their efficiency and ensure the quality of their findings. I am excited that this project provides an for an additive set of functions targeted directly at the pharmacology teams of our pharmaceutical clients and further expands the integrative value that Xybion and Pristima bring to the market."

Carlos Frade, VP of Preclinical R&D Solutions at Xybion commented, "After a diligent assessment in which Novo Nordisk and Xybion analyzed the approaches by which Pristima supports the operational planning, the data collection, the data evaluation, the instrument interfacing and efficiency improvements provided by Pristima, I am confident that we are delivering the best enterprise solution for drug discovery teams all over the world."

ABOUT XYBION
Xybion is a leading provider of software, services and consulting for global corporations operating in highly regulated industries.  Our unique solutions focus on integrated preclinical lab management, early-stage drug discovery, regulatory compliance, GRC, quality management and systems validation.

Xybion's combination of software, business process management, services, validation and staffing enables us to cover a broad spectrum of critical business needs for companies and we deliver our solutions on global scale.  Our leadership in this dynamic and ever-changing industry has been a cornerstone of our high-value reputation. To learn more, please visit www.xybion.com.

About Pristima
The Pristima® Suite is a fully integrated, end-to-end enterprise solution for tracking and managing veterinary facilities and research subjects throughout the preclinical research process. From ordering through the study submission process, the Pristima software platform delivers essential capabilities across the entire drug discovery process.   The system enables organizations to maintain all preclinical data in one system, from compound receipt through dossier submission and slide archival.  For over 35 years, global pharmaceutical companies and CROs have relied on Xybion to drive data management while ensuring quality, efficiency, and compliance. 

CONTACT: Kevin Miller, 877-617-9700

Logo - http://photos.prnewswire.com/prnh/20150930/272633LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xybion-announces-that-novo-nordisk-selects-pristima-to-manage-pharmacology-research-studies-across-all-research-sites-300152574.html

SOURCE Xybion

Copyright 2015 PR Newswire

Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novo Nordisk Charts.